AU2018360270A1 - Bicyclic sulfones and sulfoxides and methods of use thereof - Google Patents
Bicyclic sulfones and sulfoxides and methods of use thereof Download PDFInfo
- Publication number
- AU2018360270A1 AU2018360270A1 AU2018360270A AU2018360270A AU2018360270A1 AU 2018360270 A1 AU2018360270 A1 AU 2018360270A1 AU 2018360270 A AU2018360270 A AU 2018360270A AU 2018360270 A AU2018360270 A AU 2018360270A AU 2018360270 A1 AU2018360270 A1 AU 2018360270A1
- Authority
- AU
- Australia
- Prior art keywords
- dihydro
- fluoro
- triazole
- phenyl
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *c1n[n](C(CC2)c3ccccc3)c2n1 Chemical compound *c1n[n](C(CC2)c3ccccc3)c2n1 0.000 description 9
- MANGSSPTTVRWMR-FPMFFAJLSA-N CC([C@H](C1)[C@@H]1S(c1n[n]([C@@H](CC2=[F])c3ccccc3)c2n1)(=O)=O)=N Chemical compound CC([C@H](C1)[C@@H]1S(c1n[n]([C@@H](CC2=[F])c3ccccc3)c2n1)(=O)=O)=N MANGSSPTTVRWMR-FPMFFAJLSA-N 0.000 description 1
- DMYHZHLMUQCRTJ-XBZLUXOVSA-N CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccc(C)c(F)c3)c2n1)=O Chemical compound CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccc(C)c(F)c3)c2n1)=O DMYHZHLMUQCRTJ-XBZLUXOVSA-N 0.000 description 1
- QTEQIBANYQJVCU-DXCJPMOASA-N CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccccc3)c2n1)=O Chemical compound CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccccc3)c2n1)=O QTEQIBANYQJVCU-DXCJPMOASA-N 0.000 description 1
- GIESRBRNSXWZTL-XBZLUXOVSA-N CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccccc3C#N)c2n1)=O Chemical compound CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccccc3C#N)c2n1)=O GIESRBRNSXWZTL-XBZLUXOVSA-N 0.000 description 1
- ISDZHDKMMKBNSV-CGOHPFHYSA-N CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccccc3Cl)c2n1)=O Chemical compound CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2C)c3ccccc3Cl)c2n1)=O ISDZHDKMMKBNSV-CGOHPFHYSA-N 0.000 description 1
- UZSFDUXFCBBPQQ-JQWIXIFHSA-N CCOC(C(F)(F)Sc1n[n]([C@@H](C[C@@H]2C)c3ccccc3)c2n1)=O Chemical compound CCOC(C(F)(F)Sc1n[n]([C@@H](C[C@@H]2C)c3ccccc3)c2n1)=O UZSFDUXFCBBPQQ-JQWIXIFHSA-N 0.000 description 1
- NLTZPCJAFLXQLC-RCOVLWMOSA-N C[C@@H](C1)c2nc(S(C(F)(F)F)(=O)=O)n[n]2[C@@H]1c(c(F)ccc1)c1F Chemical compound C[C@@H](C1)c2nc(S(C(F)(F)F)(=O)=O)n[n]2[C@@H]1c(c(F)ccc1)c1F NLTZPCJAFLXQLC-RCOVLWMOSA-N 0.000 description 1
- RYOWOIIDHBSDLS-XVKPBYJWSA-N C[C@@H](C1)c2nc(S(C(F)F)(=O)=O)n[n]2[C@@H]1c(cc(cc1C)F)c1F Chemical compound C[C@@H](C1)c2nc(S(C(F)F)(=O)=O)n[n]2[C@@H]1c(cc(cc1C)F)c1F RYOWOIIDHBSDLS-XVKPBYJWSA-N 0.000 description 1
- GJZNGQLFDBILPM-XVKPBYJWSA-N C[C@@H](C1)c2nc(S(C(F)F)(=O)=O)n[n]2[C@@H]1c1cc(Cl)ccc1 Chemical compound C[C@@H](C1)c2nc(S(C(F)F)(=O)=O)n[n]2[C@@H]1c1cc(Cl)ccc1 GJZNGQLFDBILPM-XVKPBYJWSA-N 0.000 description 1
- QTKJAAJUVJGHKH-XVKPBYJWSA-N C[C@@H](C1)c2nc(S(C(F)F)(=O)=O)n[n]2[C@@H]1c1ccccc1F Chemical compound C[C@@H](C1)c2nc(S(C(F)F)(=O)=O)n[n]2[C@@H]1c1ccccc1F QTKJAAJUVJGHKH-XVKPBYJWSA-N 0.000 description 1
- ZZDVCRFWCHJRIP-UFNDLKIRSA-N C[C@@H](C1)c2nc(S(C(F)F)=O)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(S(C(F)F)=O)n[n]2[C@@H]1c1ccccc1 ZZDVCRFWCHJRIP-UFNDLKIRSA-N 0.000 description 1
- ZQUNSBFWHVQAGY-AAEUAGOBSA-N C[C@@H](C1)c2nc(S(C3(C)CC3)(=O)=O)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(S(C3(C)CC3)(=O)=O)n[n]2[C@@H]1c1ccccc1 ZQUNSBFWHVQAGY-AAEUAGOBSA-N 0.000 description 1
- PTWCEMBHUDMGJN-SDBXPKJASA-N C[C@@H](C1)c2nc(S(C3CC3)(=O)=O)n[n]2[C@@H]1c1cc(Cl)ccc1F Chemical compound C[C@@H](C1)c2nc(S(C3CC3)(=O)=O)n[n]2[C@@H]1c1cc(Cl)ccc1F PTWCEMBHUDMGJN-SDBXPKJASA-N 0.000 description 1
- PNIGTBHRZPFEPD-HZMBPMFUSA-N C[C@@H](C1)c2nc(S(C3CC3)(=O)=O)n[n]2[C@@H]1c1ccc(C)c(F)c1 Chemical compound C[C@@H](C1)c2nc(S(C3CC3)(=O)=O)n[n]2[C@@H]1c1ccc(C)c(F)c1 PNIGTBHRZPFEPD-HZMBPMFUSA-N 0.000 description 1
- FRNHHKRMWIBKJB-ONGXEEELSA-N C[C@@H](C1)c2nc(S(CF)(=O)=O)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(S(CF)(=O)=O)n[n]2[C@@H]1c1ccccc1 FRNHHKRMWIBKJB-ONGXEEELSA-N 0.000 description 1
- MGBREMIWCRGNRV-YOEHRIQHSA-N C[C@@H](C1)c2nc(S(Cc3ccccc3)(=O)=O)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(S(Cc3ccccc3)(=O)=O)n[n]2[C@@H]1c1ccccc1 MGBREMIWCRGNRV-YOEHRIQHSA-N 0.000 description 1
- MVBWEVHZVLZWAS-YKKKNFCPSA-N C[C@@H](C1)c2nc(S([C@@H](CC3)C3(F)F)(=O)=O)n[n]2[C@@H]1C1(C)C=CC=CC1 Chemical compound C[C@@H](C1)c2nc(S([C@@H](CC3)C3(F)F)(=O)=O)n[n]2[C@@H]1C1(C)C=CC=CC1 MVBWEVHZVLZWAS-YKKKNFCPSA-N 0.000 description 1
- HXFSHXHGTIIEAF-WPRPVWTQSA-N C[C@@H](C1)c2nc(S)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(S)n[n]2[C@@H]1c1ccccc1 HXFSHXHGTIIEAF-WPRPVWTQSA-N 0.000 description 1
- XITNJXISTVQJCE-LLGZUXRYSA-N C[C@@H](C1)c2nc(SC(C3)CC3C(OC)=O)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(SC(C3)CC3C(OC)=O)n[n]2[C@@H]1c1ccccc1 XITNJXISTVQJCE-LLGZUXRYSA-N 0.000 description 1
- SCCQAMXMDBMHLY-QCZWPSDZSA-N C[C@@H](C1)c2nc(SC(F)F)n[n]2[C@@H]1C(CC=C1C)C=C1F Chemical compound C[C@@H](C1)c2nc(SC(F)F)n[n]2[C@@H]1C(CC=C1C)C=C1F SCCQAMXMDBMHLY-QCZWPSDZSA-N 0.000 description 1
- KSUQWFKUJRHNML-GWCFXTLKSA-N C[C@@H](C1)c2nc(SC3CC3)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(SC3CC3)n[n]2[C@@H]1c1ccccc1 KSUQWFKUJRHNML-GWCFXTLKSA-N 0.000 description 1
- NMHWFXVIKXVLCG-ONGXEEELSA-N C[C@@H](C1)c2nc(SCF)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(SCF)n[n]2[C@@H]1c1ccccc1 NMHWFXVIKXVLCG-ONGXEEELSA-N 0.000 description 1
- LSAUIRGRTKFKEA-JURCDPSOSA-N C[C@@H](C1)c2nc(S[C@H](C3)C[C@@H]3C#N)n[n]2[C@@H]1c1ccccc1 Chemical compound C[C@@H](C1)c2nc(S[C@H](C3)C[C@@H]3C#N)n[n]2[C@@H]1c1ccccc1 LSAUIRGRTKFKEA-JURCDPSOSA-N 0.000 description 1
- ZWZKJXCPIANXCV-HMDFOJMHSA-N C[C@@H](C1)c2nc([S@@](CF)=O)n[n]2[C@@H]1c(c(F)ccc1)c1F Chemical compound C[C@@H](C1)c2nc([S@@](CF)=O)n[n]2[C@@H]1c(c(F)ccc1)c1F ZWZKJXCPIANXCV-HMDFOJMHSA-N 0.000 description 1
- ZEVHGJHWHVALGC-UHFFFAOYSA-N FC(C1)c2nc(S)n[n]2C1c(cccc1)c1F Chemical compound FC(C1)c2nc(S)n[n]2C1c(cccc1)c1F ZEVHGJHWHVALGC-UHFFFAOYSA-N 0.000 description 1
- HDVYANNOFJRHST-UWVGGRQHSA-N FC(F)Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2c1 Chemical compound FC(F)Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2c1 HDVYANNOFJRHST-UWVGGRQHSA-N 0.000 description 1
- KYAXWGRIOQZKSH-PVUDRZGPSA-N N#CC[S@@](c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2c1)=O Chemical compound N#CC[S@@](c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2c1)=O KYAXWGRIOQZKSH-PVUDRZGPSA-N 0.000 description 1
- KYAXWGRIOQZKSH-JOOBJXAISA-N N#CC[S@](c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2c1)=O Chemical compound N#CC[S@](c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2c1)=O KYAXWGRIOQZKSH-JOOBJXAISA-N 0.000 description 1
- VWPWNGFMOWDGKS-VOAKCMCISA-N N#C[C@@H](C1)[C@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound N#C[C@@H](C1)[C@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O VWPWNGFMOWDGKS-VOAKCMCISA-N 0.000 description 1
- AAYXHUDRDDRJDB-GHYVTOPFSA-N NC[C@H](C1)C[C@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound NC[C@H](C1)C[C@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O AAYXHUDRDDRJDB-GHYVTOPFSA-N 0.000 description 1
- PVFXYNCWFGGITH-UHFFFAOYSA-N O=S(C(F)F)(c1n[n](CCC2c3ccccc3)c2n1)=O Chemical compound O=S(C(F)F)(c1n[n](CCC2c3ccccc3)c2n1)=O PVFXYNCWFGGITH-UHFFFAOYSA-N 0.000 description 1
- YAOPMPMOGSDDNA-VIFPVBQESA-N O=S(C(F)F)(c1n[n]([C@@H](CC2)c(cccc3)c3Cl)c2n1)=O Chemical compound O=S(C(F)F)(c1n[n]([C@@H](CC2)c(cccc3)c3Cl)c2n1)=O YAOPMPMOGSDDNA-VIFPVBQESA-N 0.000 description 1
- YAOPMPMOGSDDNA-SECBINFHSA-N O=S(C(F)F)(c1n[n]([C@H](CC2)c3ccccc3Cl)c2n1)=O Chemical compound O=S(C(F)F)(c1n[n]([C@H](CC2)c3ccccc3Cl)c2n1)=O YAOPMPMOGSDDNA-SECBINFHSA-N 0.000 description 1
- ZXDSENGCMPHIPS-JKQPQIASSA-N O=S(CC(F)(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3[F]C(CS(c3n[n]([C@@H](C[C@@H]4F)c5ccccc5)c4n3)(=O)=O)(F)F)c2n1 Chemical compound O=S(CC(F)(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3[F]C(CS(c3n[n]([C@@H](C[C@@H]4F)c5ccccc5)c4n3)(=O)=O)(F)F)c2n1 ZXDSENGCMPHIPS-JKQPQIASSA-N 0.000 description 1
- DPTIEINIKPCVPF-OVEOACLYSA-N O=S(CC1CC1)c1n[n]([C@@H](C[C@@H]2F)c3c(C4C(CS(c5n[n]([C@@H](C[C@@H]6F)c7ccccc7)c6n5)(=O)=O)C4)cccc3)c2n1 Chemical compound O=S(CC1CC1)c1n[n]([C@@H](C[C@@H]2F)c3c(C4C(CS(c5n[n]([C@@H](C[C@@H]6F)c7ccccc7)c6n5)(=O)=O)C4)cccc3)c2n1 DPTIEINIKPCVPF-OVEOACLYSA-N 0.000 description 1
- YLRKXPGENSDCSP-MMXNHZJYSA-N O=[S@](C(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=[S@](C(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 YLRKXPGENSDCSP-MMXNHZJYSA-N 0.000 description 1
- LJMOPQQDZHQDDM-QWRGUYRKSA-N OC(C1(CC1)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O)O Chemical compound OC(C1(CC1)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O)O LJMOPQQDZHQDDM-QWRGUYRKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579392P | 2017-10-31 | 2017-10-31 | |
| US62/579,392 | 2017-10-31 | ||
| PCT/EP2018/079772 WO2019086494A1 (en) | 2017-10-31 | 2018-10-30 | Bicyclic sulfones and sulfoxides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018360270A1 true AU2018360270A1 (en) | 2020-03-26 |
Family
ID=64051580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018360270A Abandoned AU2018360270A1 (en) | 2017-10-31 | 2018-10-30 | Bicyclic sulfones and sulfoxides and methods of use thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11072617B2 (https=) |
| EP (1) | EP3704097B1 (https=) |
| JP (1) | JP2021501183A (https=) |
| KR (1) | KR20200083515A (https=) |
| CN (1) | CN111278809B (https=) |
| AR (1) | AR113811A1 (https=) |
| AU (1) | AU2018360270A1 (https=) |
| BR (1) | BR112020008446A2 (https=) |
| CA (1) | CA3078688A1 (https=) |
| CL (1) | CL2020001062A1 (https=) |
| CO (1) | CO2020003475A2 (https=) |
| CR (1) | CR20200168A (https=) |
| IL (1) | IL273847A (https=) |
| MA (1) | MA50503A (https=) |
| MX (1) | MX2020003451A (https=) |
| PE (1) | PE20211247A1 (https=) |
| PH (1) | PH12020550537A1 (https=) |
| RU (1) | RU2020115915A (https=) |
| SG (1) | SG11202002877RA (https=) |
| TW (1) | TW201922748A (https=) |
| WO (1) | WO2019086494A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11098058B2 (en) | 2017-07-14 | 2021-08-24 | Genentech, Inc. | Bicyclic ketone compounds and methods of use thereof |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
| CN113302193A (zh) | 2019-01-11 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| WO2023083847A1 (en) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines as ripk1 inhibitors and use thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) * | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) * | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| RU2628616C2 (ru) | 2011-11-03 | 2017-08-21 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения пиперазина |
| EP2852584B1 (en) | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
| CA2896187A1 (en) | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| CA2907912A1 (en) | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| PH12019502378A1 (en) | 2013-05-01 | 2022-05-11 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
| WO2015006280A1 (en) | 2013-07-10 | 2015-01-15 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| WO2016142310A1 (en) | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Tricyclic dlk inhibitors and uses thereof |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| US10751444B2 (en) | 2015-08-07 | 2020-08-25 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| WO2017109724A1 (en) * | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) * | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| US11180493B2 (en) | 2016-11-08 | 2021-11-23 | Cyclerion Therapeutics, Inc. | SGC stimulators |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US11098058B2 (en) | 2017-07-14 | 2021-08-24 | Genentech, Inc. | Bicyclic ketone compounds and methods of use thereof |
| PE20211246A1 (es) | 2017-10-11 | 2021-07-13 | Hoffmann La Roche | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa |
| SG11202002877RA (en) | 2017-10-31 | 2020-04-29 | Hoffmann La Roche | Bicyclic sulfones and sulfoxides and methods of use thereof |
-
2018
- 2018-10-30 SG SG11202002877RA patent/SG11202002877RA/en unknown
- 2018-10-30 AR ARP180103157A patent/AR113811A1/es unknown
- 2018-10-30 PE PE2020000353A patent/PE20211247A1/es unknown
- 2018-10-30 AU AU2018360270A patent/AU2018360270A1/en not_active Abandoned
- 2018-10-30 CN CN201880070578.0A patent/CN111278809B/zh active Active
- 2018-10-30 US US16/175,206 patent/US11072617B2/en active Active
- 2018-10-30 CA CA3078688A patent/CA3078688A1/en active Pending
- 2018-10-30 KR KR1020207015138A patent/KR20200083515A/ko not_active Ceased
- 2018-10-30 RU RU2020115915A patent/RU2020115915A/ru unknown
- 2018-10-30 MX MX2020003451A patent/MX2020003451A/es unknown
- 2018-10-30 TW TW107138469A patent/TW201922748A/zh unknown
- 2018-10-30 WO PCT/EP2018/079772 patent/WO2019086494A1/en not_active Ceased
- 2018-10-30 CR CR20200168A patent/CR20200168A/es unknown
- 2018-10-30 JP JP2020524177A patent/JP2021501183A/ja active Pending
- 2018-10-30 MA MA050503A patent/MA50503A/fr unknown
- 2018-10-30 EP EP18796020.8A patent/EP3704097B1/en active Active
- 2018-10-30 BR BR112020008446-8A patent/BR112020008446A2/pt not_active Application Discontinuation
-
2020
- 2020-03-25 CO CONC2020/0003475A patent/CO2020003475A2/es unknown
- 2020-04-06 IL IL273847A patent/IL273847A/en unknown
- 2020-04-20 CL CL2020001062A patent/CL2020001062A1/es unknown
- 2020-04-30 PH PH12020550537A patent/PH12020550537A1/en unknown
-
2021
- 2021-06-06 US US17/340,082 patent/US12338241B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3704097B1 (en) | 2023-10-25 |
| EP3704097C0 (en) | 2023-10-25 |
| IL273847A (en) | 2020-05-31 |
| CN111278809A (zh) | 2020-06-12 |
| EP3704097A1 (en) | 2020-09-09 |
| US11072617B2 (en) | 2021-07-27 |
| JP2021501183A (ja) | 2021-01-14 |
| AR113811A1 (es) | 2020-06-10 |
| SG11202002877RA (en) | 2020-04-29 |
| KR20200083515A (ko) | 2020-07-08 |
| MA50503A (fr) | 2020-09-09 |
| BR112020008446A2 (pt) | 2020-12-29 |
| RU2020115915A (ru) | 2021-12-01 |
| CA3078688A1 (en) | 2019-05-09 |
| US20230002391A1 (en) | 2023-01-05 |
| CL2020001062A1 (es) | 2020-08-21 |
| MX2020003451A (es) | 2020-08-03 |
| RU2020115915A3 (https=) | 2022-05-06 |
| PE20211247A1 (es) | 2021-07-13 |
| US20190127382A1 (en) | 2019-05-02 |
| WO2019086494A1 (en) | 2019-05-09 |
| CR20200168A (es) | 2020-07-12 |
| US12338241B2 (en) | 2025-06-24 |
| CN111278809B (zh) | 2024-06-25 |
| TW201922748A (zh) | 2019-06-16 |
| CO2020003475A2 (es) | 2020-04-24 |
| PH12020550537A1 (en) | 2021-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12338241B2 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| EP3781571B1 (en) | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) | |
| EP3526219B1 (en) | Bicyclic pyridone lactams and methods of use thereof | |
| US11607396B2 (en) | Bicyclic amide compounds and methods of use thereof | |
| US11834461B2 (en) | Bicyclic ketone compounds and methods of use thereof | |
| EP3694858B1 (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| US20250282788A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| RU2797922C2 (ru) | Бициклические кетоны и способы их применения | |
| HK40024493B (zh) | 二环碸类和亚碸类、以及其使用方法 | |
| HK40024493A (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| HK40062362B (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40062362A (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |